ASMB 6.69 - 57% *Assembly Biosciences shares are trading lower after the company announced its HBV field core inhibitor combination study did not achieve endpoints. Benzinga
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.